Corium Announces Issuance of Key U.S. Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease

- June 13th, 2018

Corium (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office (PTO) has issued a cornerstone patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-weekly patch that delivers the most commonly prescribed medication for … Continued

Corium (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office (PTO) has issued a cornerstone patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-weekly patch that delivers the most commonly prescribed medication for Alzheimer’s patients.

As quoted in the press release:

“Our novel Corplex TDS design and formulation technologies were enabling for the once-weekly transdermal delivery of Donepezil,” said Parminder “Bobby” Singh, Ph.D., Chief Technology Officer and Vice President, R&D at Corium, and a co-inventor on the patent.  “The issuance of this patent highlights our innovation in the transdermal delivery of molecules such as donepezil that have previously been very challenging to transport across the skin with traditional patch technologies.”

The new patent is eligible for listing in the U.S. FDA Orange Book, and its life extends at least to July 2037.  It is the first to issue of a series of pending Corium patent applications relating to various aspects of Corplex Donepezil, as well as similar products.

Click here to read the full press release.

Biotech Stocks in 2018

 
Find out how the market will look this year

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *